ArticleBioinformatics advances2026
DeepFRAG: a method for cancer detection based on DNA fragmentomics and deep learning.
Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Cancer screening using liquid biopsy technology has become standard in modern clinical and preventive oncology. This method analyzes cell-free DNA (cfDNA) circulating in a patient's bloodstream. While mutation-based diagnostics using deep exome sequencing are highly sensitive and specific, an alternative approach involves examining cfDNA fragment size distribution profiles. This method is less expensive and can be derived from low-depth whole genome sequencing (WGS). Results: Our study presents DeepFRAG: a new cancer detection method based on deep learning analysis of cfDNA fragment size distribution profiles using wavelet transform. We utilized two independent cohorts comprising 73 patients with stage III and IV cancers (breast, colorectal, pancreatic, lung, and liver) and 80 healthy individuals. We introduced an original data augmentation technique specific to WGS fragment size data, ensuring sufficient data for training the deep learning model. The proposed method demonstrated high accuracy, with a median test AUROC (area under the receiver operating characteristic curve) of 0.974 and a sensitivity of 96.1% at 98.8% specificity. Our approach offers several advantages, including high accuracy, cost-effectiveness, robustness, and suitability for detecting major cancer types. This method represents a promising advancement in cancer screening technology, expanding the options available for noninvasive cancer detection, with the goal of improving patient outcomes. Availability and implementation: Data and source code are available at https://github.com/andreykoch/DeepFRAG.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.